4.7 Article

Exploration of inhibitors for diaminopimelate aminotransferase

Journal

BIOORGANIC & MEDICINAL CHEMISTRY
Volume 18, Issue 6, Pages 2141-2151

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2010.02.001

Keywords

Lysine biosynthesis; Aminotransferase; Diaminopimelate (DAP); Arabidopsis thaliana; Pyridoxal-5 '-phosphate (PLP); Chlamydia; Enzyme inhibition

Funding

  1. Natural Sciences and Engineering Research Council of Canada (NSERC)
  2. Alberta Heritage Foundation for Medical Research (AHFMR)
  3. Canada Research Chair in Bioorganic and Medicinal Chemistry

Ask authors/readers for more resources

Bacteria and higher plants make L-lysine from diaminopimelic acid (DAP). In mammals L-lysine is an essential amino acid that must be acquired from the diet as the biosynthetic pathway is absent for this key constituent of proteins. Recently, LL-diaminopimelate aminotransferase (LL-DAP-AT), a pyridoxal-5'-phosphate (PLP)-dependent enzyme, was reported to catalyze a key step in the route to L-lysine in plants and Chlamydia. Specific inhibitors of this enzyme could thus potentially serve as herbicides or antibiotics that are non-toxic to mammals. In this work, 29,201 inhibitors were screened against LL-DAP-AT and the IC50 values were determined for the top 46 compounds. An aryl hydrazide and rhodanine derivatives were further modified to generate 20 analogues that were also tested against LL-DAP-AT. These analogues provide additional structure-activity relationships (SAR) that are useful in guiding further design of inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available